The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...
MM survival rates have improved with the introduction of novel agents. Treatment of MM within the first year is associated with improved survival. New research has concluded that, despite more ...
Using nationwide electronic health record (EHR) and cancer registry data from the VA Corporate Data Warehouse, we developed and validated a rule-based NLP algorithm to extract oncologist-determined MM ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment ...
Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...
All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...
Development and Validation of Dynamic 5-Year Breast Cancer Risk Model Using Repeated Mammograms Using nationwide electronic health record (EHR) and cancer registry data from the VA Corporate Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback